Active Ingredient(s): Trifluridine + Tipiracil
FDA Approved: * September 22, 2015
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Lonsurf Overview

Trifluridine/tipiracil, sold under the brand name Lonsurf, is a fixed-dose combination medication that is used as a third- or fourth-line treatment of metastatic colorectal cancer or gastric cancer, after chemotherapy and targeted therapeutics have failed.[2][3] It is a combination of two active pharmaceutical ingredients: trifluridine, a nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor.[2][3] Tipiracil prev...

Read more Lonsurf Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Trifluridine/tipiracil

Recent Lonsurf Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Trifluridine + Tipiracil
  • Tablet: 15mg, 20mg, 6.14mg + 15mg, 8.19mg + 20mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Lonsurf: (2 results)

Sorted by National Drug Code
  • 64842-1020 Lonsurf Oral Tablet, Film Coated by Taiho Pharmaceutical Co., Ltd.
  • 64842-1025 Lonsurf Oral Tablet, Film Coated by Taiho Pharmaceutical Co., Ltd.

Drugs with one or more similar ingredients: (3 results)